IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT
Kong, Y.1; Xu, L-P1; Liu, Y-R1; Qin, Y-Z1; Sun, Y-Q1; Wang, Y.1; Jiang, H.1; Jiang, Q.1; Chen, H.1; Chang, Y-J1; Huang, X-J1,2
刊名BONE MARROW TRANSPLANTATION
2015-03-01
DOI10.1038/bmt.2014.274
50期:3页:348-353
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]ACUTE LYMPHOBLASTIC-LEUKEMIA ; ACUTE MYELOID-LEUKEMIA ; MINIMAL RESIDUAL DISEASE ; MULTICOLOR FLOW-CYTOMETRY ; POLYMERASE-CHAIN-REACTION ; TRANSCRIPT LEVELS ; CANCER PROGRAM ; IMATINIB ; TRANSPLANTATION ; SURVIVAL
英文摘要

Relapse of Ph chromosome-positive ALL (Ph(+)ALL) results from the persistence of leukemia-propagating cells (LPCs). In Ph(+)ALL, a xenograft assay recently determined that LPCs are enriched in the CD34(+)CD38(-)CD58(-) fraction. Therefore, the prognostic significance of LPCs in Ph+ALL subjects after allogeneic hematopoietic SCT (allo-HSCT) was investigated. A total of 80 consecutive adults with Ph+ALL who underwent allo-HSCT were eligible. A multi-parameter flow cytometry analysis examining CD58-FITC/CD10-PE/CD19-APC-Cy7/CD34-PerCP/CD45-Vioblue/CD38-APC on gated leukemia BM blasts was performed at diagnosis. Based on the original blast phenotypes, subjects were stratified into the CD34(+)CD38(-)CD58(-) group (N = 15) and other phenotype group (N = 65). During minimal residual disease monitoring, significantly higher levels of BCR/ABL transcripts were detected in subjects in the CD34(+)CD38(-)CD58(-) group than in other phenotype group, especially at 3 months post HSCT. In addition, CD34(+)CD38(-)CD58(-) LPCs are directly correlated with a higher 3-year cumulative incidence of relapse (CIR) and worse leukemia-free survival (LFS) and OS. Multivariate analyses indicated that presence of CD34(+)CD38(-)CD58(-) LPCs at diagnosis, and BCR-ABL reduction at 3 months post HSCT were independent risk factors for relapse, LFS and OS. Our data suggest that presence of CD34(+)CD38(-)CD58(-) LPCs at diagnosis allows rapid identification of high-risk patients for relapse after allo-HSCT.

语种英语
WOS记录号WOS:000351632000005
项目编号81370638 ; 81230013 ; RDB2012-23
资助机构National Natural Science Foundation of China ; Beijing Municipal Science and Technology Program ; National Clinical Priority Specialty ; Peking University People&prime ; s Hospital Research and Development Funds
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53316
专题北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Kong, Y.,Xu, L-P,Liu, Y-R,et al. Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT[J]. BONE MARROW TRANSPLANTATION,2015,50(3):348-353.
APA Kong, Y..,Xu, L-P.,Liu, Y-R.,Qin, Y-Z.,Sun, Y-Q.,...&Huang, X-J.(2015).Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.BONE MARROW TRANSPLANTATION,50(3),348-353.
MLA Kong, Y.,et al."Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT".BONE MARROW TRANSPLANTATION 50.3(2015):348-353.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Kong, Y.]的文章
[Xu, L-P]的文章
[Liu, Y-R]的文章
百度学术
百度学术中相似的文章
[Kong, Y.]的文章
[Xu, L-P]的文章
[Liu, Y-R]的文章
必应学术
必应学术中相似的文章
[Kong, Y.]的文章
[Xu, L-P]的文章
[Liu, Y-R]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。